Safety and effectiveness of ambrisentan in real clinical practice in pulmonary arterial hypertension: Results from the Korean post-marketing surveillance.
Kina JeonSang-Bae YooYoonhee LeeEun-Bin LeeHyung Kwan KimSeo Young SongSung-A ChangPublished in: Pharmacoepidemiology and drug safety (2023)
In real-world practice, ambrisentan demonstrated tolerable safety and favorable effectiveness in PAH patients in Korea. Age and concomitant drug use can affect the occurrence of AE.
Keyphrases
- pulmonary arterial hypertension
- randomized controlled trial
- end stage renal disease
- clinical practice
- systematic review
- pulmonary artery
- pulmonary hypertension
- newly diagnosed
- ejection fraction
- healthcare
- public health
- chronic kidney disease
- risk assessment
- peritoneal dialysis
- coronary artery
- patient reported outcomes
- quality improvement
- patient reported
- polycyclic aromatic hydrocarbons